Altasciences, a CRO in the U.S. and Canada specializing in a flexible, innovative approach to comprehensive early stage drug development, has entered into an agreement with Amador Bioscience, a translational and consulting clinical research organization located in China and the U.S. This partnership aims to expand world-class capabilities and resources to promote drug development in China and North America. 
 
“We are excited to collaborate with Amador Bioscience’s dedicated team of diverse experts, particularly in support of China’s fast-growing and innovative biotech industry,” said Steve Mason, Executive Vice President, Altasciences. 
 
Altasciences and Amador Bioscience will collaborate on IND-enabling preclinical studies, design and conduct of early-stage clinical programs, including first-in-human and proof-of-concept trials, as well as provide end-to-end solutions, such as laboratory services, to transpacific drug development programs.
 
“We are pleased to be partnering with Altasciences, offering our clients access to world-class preclinical and clinical facilities, personalized services, and 25 years’ expertise in conducting successful clinical trials,” said Xiaomin Chen, General Manager, Amador Bioscience. “Our synergistic and effective collaboration will surely expedite the development of novel therapeutics.”